🔗 Share this article

The first new treatments for gonorrhoea in decades are being viewed as a "significant breakthrough" in the fight against superbug strains of the infection, according to scientists.

A Global Health Concern

Cases of gonorrhoea are escalating globally, with data suggesting over 82 million new cases per year. Notably increased rates are seen in Africa and nations within the WHO's designated area, which encompasses China and Mongolia to New Zealand. Across England, cases have hit a all-time high, while rates across Europe in 2023 were three times higher compared to figures for 2014.

“The authorization of novel therapies for gonorrhoea is an critical and opportune step in the face of increasing worldwide cases, increasing antimicrobial resistance and the highly restricted therapeutic options presently on offer.”

Public health authorities are deeply concerned about the surge in antibiotic-resistant strains. The World Health Organization has classified it as a "critical concern". A tracking program found that the effectiveness of standard treatments like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

Recent Drugs Receive Authorization

Zoliflodacin, also known as Nuzolvence, was cleared by the US FDA in recent days for combating gonorrhoea. This disease can lead to serious health problems, including infertility. Scientists hope that focused deployment of this new drug will help delay the emergence of superbugs.

Gepotidacin, created by the pharmaceutical company GSK, gained clearance in close succession. This treatment, which is also used to treat UTIs, was proven in research to be able to combat drug-resistant strains of the gonorrhoea bacteria.

A Novel Partnership

This new treatment was the result of a innovative non-profit model for drug creation. The charitable organization Global Antibiotic Research & Development Partnership collaborated with the drug firm Innoviva to develop it.

“This authorization signifies a huge turning point in the treatment of multidrug-resistant gonorrhoea, which previously has been outpacing antibiotic development.”

Research Study Data and Global Access

As per data detailed in a prominent scientific publication, the new drug successfully treated over nine in ten of genital gonorrhoea infections. This puts it on an equal footing with the current standard treatment, which uses an injection and a pill. The research enrolled over 900 patients from multiple nations including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its unique model, GARDP has the rights to license and sell the drug in many developing nations.

Clinicians directly involved have expressed positive views. The availability of a single-dose, oral treatment of this kind is seen as a "game-changer" for managing the epidemic. This is viewed as crucial to lessen the impact of the disease for people and to halt the transmission of untreatable gonorrhoea around the world.